Abstract
In common with most infectious agents, meningococci invade mucosal membranes before causing disease (1). An attractive vaccine strategy is therefore to induce immunological responses at the mucosal surfaces, with the possibility of blocking microbial invasion, as well as to induce systemic immunity with the capacity of inactivating the microbes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Griffiss, J. M. (1995) Mechanisms of host immunity, in Meningococcal Disease (Cartwright, K. A. V., ed.), John Wiley and Sons, Chichester, UK, pp. 35–70.
Ala’Aldeen, D. A. A., and Griffiths, E. (1995) Vaccines against meningococcal Disease, in Molecular and Clinical Aspects of Bacterial Vaccine Development (Ala’Aldeen, D. A. A. and Hormaeche, C. E., eds.) John Wiley and Sons, Chichester, UK, pp. 1–39.
Brandtzaeg, P., Farstad, I. N., Johansen, F.-E., Morton, H. C., Norderhagen, I. N., and Yamanaka, T. (1999) The B-cell system of human mucosae and exocrine glands. Immunol. Rev. 171, 45–87.
McGhee, J. R., Mestecky, J., Dertzbaugh, M. T., Eldridge, J. H., Hirasawa, M., and Kiyono, H. (1992) The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10, 75–88.
Walker, R. I. (1994) New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12, 387–400.
Haneberg, B., Dalseg, R., Wedege, E., Høiby, E. A., Haugen, I. L., Oftung, F., et al. (1998) Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. 66, 1334–1341.
Drabick, J. J., Brandt, B. L., Moran, E. E., Saunders, N. B., Shoemaker, D. R., and Zollinger, W. D. (2000) Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine 18, 160–172.
Tang, C., Moxon, R., and Levine, M. M. (1999) For discussion: live attenuated vaccines for group B meningococcus. Vaccine 17, 114–117.
American Academy of Pediatrics, Committee on Infectious Diseases (1999) Prevention of poliomyelitis: recommendations for use of only inactivated poliovirus vaccine for routine immunization. Pediatrics 104, 1404–1406.
Bitnun, A., Shannon, P., Durward. A., Rota, P. A., Bellini, W. J., Graham, C., et al. (1999) Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin. Infect. Dis. 29, 855–861.
Centers for Disease Control and Prevention (1999) Intussuspection among recipients of rotavirus vaccine: United States, 1998–1999. MMWR Morb. Mortal. Wkly. Rep. 48, 577–581.
Talbot, E. A., Perkins, M. D., Silva, S. F. M., and Frothingham, R. (1997) Disseminated Bacille Calmette-Guérin disease after vaccination: case report and review. Clin. Infect. Dis. 24, 1139–1146.
van Loon, F. P. L., Clemens, J. D., Chakraborty, J., Rao, M. R., Kay, B. A., Sack, D. A., et al. (1996) Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years follow-up. Vaccine 14, 162–166.
Richman, L. K., Chiller, J. M., Brown, W. R., Hanson, D. G., and Vaz, N. M. (1978) Enterically induced immunologic tolerance. I. Induction of suppressor T lymphocytes by intragastric administration of soluble proteins. J. Immunol. 121, 2429–2434.
Ogra, P. L. (1996) Mucosal immunoprophylaxis: an introductory overview, in Mucosal Vaccines (Kiyono, H., Ogra, P. L., and McGhee, J. R., eds.), Academic Press, San Diego, CA, pp. 3–14.
Levine, M. M. and Dougan, G. (1998) Optimism over vaccines administered via mucosal surfaces. Lancet 351, 1375–1376.
Holmgren, J., Lycke, N., and Czerkinsky, C. (1993) Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11, 1179–1184.
Agren, L., Lowenadler, B., and Lycke, N. (1998) A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol. Cell. Biol. 76, 280–287.
Douce, G., Giannelli, V., Pizza, M., Lewis, D., Everest, P., Rappuoli, R., and Dougan, G. (1999) Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect. Immun. 67, 4400–4406.
Sun, J.-B., Rask, C., Olsson, T., Holmgren, J., and Czerkinsky, C. (1996) Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Natl. Acad. Sci. USA 93, 7196–7201.
Dalseg, R., Wedege, E., Holst, J., Haugen, I. L., Høiby, E. A., and Haneberg, B. (1999) Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice. Vaccine 17, 2336–2345.
Hvalbye, B. K. R., Aaberge, I. S., Løvik, M., and Haneberg, B. (1999) Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect. Immun. 67, 4320–4325.
Hordnes, K., Tynning, T., Brown, T. A., Haneberg, B., and Jonsson, R. (1997) Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice. Vaccine 15, 1244–1251.
Berstad, A. K. H., Holst, J., Møgster, B., Haugen, I. L., and Haneberg, B. (1997) A nasal whole-cell pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin. Vaccine 15, 1473–1478.
Oftung, F., Næss, L. M., Wetzler, L. M., Korsvold, G. E., Aase, A., Høiby, E. A., et al. (1999) Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect. Immun. 67, 921–927.
Berstad, A. K. H., Holst, J., Frøholm, L. O., Haugen, I. L., Wedege, E., Oftung, F., and Haneberg, B. (2000) A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J. Med. Microbiol. 49, 157–163.
Dalseg, R., Holst, J., Tangen, T., Stabbetorp, G., Simonsen, P., Jantzen, E., et al. (1996) Outer membrane vesicles from group B meningococci can act as mucosal adjuvant for influenza virus antigens, in Vaccine 96; Molecular Approaches to the Control of Infectious Diseases (Brown, E., Norrby, E., Burton, D., and Mekalanos, J., eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 177–182.
Berstad, A. K. H., Andersen, S. R., Dalseg, R., Drømtorp, S., Holst, J., Namork, E., et al. (2000) Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine. Vaccine 18, 1910–1919.
Bergquist, C., Johansson, E.-L., Lagergård, T., Holmgren, J., and Rudin A. (1997) Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and vagina. Infect. Immun. 65, 2676–2684.
Del Giudice, G. and Rappuoli, R. (1999) Genetically derived toxoids for use as vaccines and adjuvants. Vaccine 17, S44–S52.
Quraishi, M. S., Jones, N. S., and Mason, J. D. T. (1997) The nasal delivery of drugs. Clin. Otolaryngol. 22, 289–301.
Lale, A. M., Mason, J. D. T., and Jones, N. S. (1998) Mucociliary transport and its assessment: a review. Clin. Otolaryngol. 23, 388–396.
Winther, B. and Innes, D.J. (1994) The human adenoid. A morphologic study. Arch. Otolaryngol. Head. Neck. Surg. 120, 144–149.
Anonymous (1997) Nasal preparations. Ph. Eur. 3rd Ed. (Council of Europe, Strasbourgh Cedex) pp. 1763–1765.
Anonymous (1997) Parenteral preparations. Ph. Eur. 3rd Ed. (Council of Europe, Strasbourgh Cedex) pp. 1765–1767.
Holst Fredriksen, J., Rosenqvist, E., Wedege, E., Bryn, K., Bjune, G., Frøholm, L. O., et al. (1991) Production, characterization, and control of Men B-vaccine “Folkehelsa”: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14, 67–79.
Claassen, I., Meylis, J., van der Ley, P., Peeters, C., Brons, H., Robert, J., et al. (1996) Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14, 1001–1008.
Hammon, S. and Egelberg, P. (1999) Particle size and shape measurement by automated microscopy. Eur. Pharm. Rev. 4, 16–20.
Anger, S., Caldwell, K., Niehus, H., and Müller, R. H. (1999) High resolution size determination of 20 nm colloidal gold particles by SedFFF. Pharm. Res. 16, 1743–1747.
Woodle, M. C., Collins, L. R., Sponsler, E., Kossovsky, N., Papahadjopoulos, D., and Martin, F. J. (1992) Sterically stabilized liposomes. Biophys. J. 61, 902–910.
Haneberg, B., Huynh, P., Nordsaeter, T., Haugen, I. L., Holst, J., and Aaberge, I. S. (1999) Intranasal immunization can generate better antibody responses when the antigen is given repeatedly in small doses. Immunol. Lett. 69, 177.
Bakke, H., Haugen, I. L., Lie, K., Korsvold, G. E., Holst, J., Aaberge, I. S., et al. (1999) A bacterial outer membrane vesicle vaccine given intranasally can induce immunological memory with strong booster responses. Immunol. Lett. 69, 178.
Haneberg, B., Kendall, D., Amerongen, H. M., Apter, F. M., Kraenhbuhl, J.-P., and Neutra, M. R. (1994) Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect. Immun. 62, 15–23.
Haneberg, B., Kendall, D., Apter, F. M., and Neutra, M. R. (1997) Distribution of monoclonal antibodies in intestinal and urogenital secretions of mice bearing hybridoma ‘backpack’ tumours. Scand. J. Immunol. 45, 151–159.
Vetvik, H., Grewal, H. M. S., Haugen, I. L., Åhrén, C., and Haneberg, B. (1998) Mucosal antibodies can be measured in air-dried samples of saliva and feces. J. Immunol. Meth. 215, 163–172.
Berstad, A. K. H., Oftung, F., Korsvold, G. E., Haugen, I. L., Frøholm, L. O., Holst, J., and Haneberg B. (2000) Induction of antigen-specific T cell responses in humans after intranasal immunization with a whole-cell pertussis vaccine. Vaccine 18, 2323–2330.
Perkins, B. A., Jonsdottir, K., Briem, H., Griffiths, E., Plikaytis, B. D., Høiby, E. A., et al. (1998) Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177, 683–691.
Fuglesang, J.E., Høiby, E. A., Holst, J., Rosenqvist, E., and Nøkleby H. (1998) Increased and longer-lasting immune responses to the Norwegian meningococcal group B OMV vaccine in teenagers with a three-dose compared to a two-dose regimen, in Eleventh International Pathogenic Neisseria Conference (Nassif, X., Quentin-Millet, M.-J., and Taha, M.-K., eds.), Editions EDK, Paris, France, p. 174.
Bergquist, C., Lagergård, T., and Holmgren, J. (1997) Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate. Infect. Immun. 65, 1579–1583.
Wedege, E., Bryn, K., and Frøholm, L. O. (1998) Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents. J. Immunol. Methods 113, 51–59.
Høiby, E. A., Rosenqvist, E., Frøholm, L. O., Bjune, G., Feiring, B., Nøkleby, H., and Rønnild, E. (1991) Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann. 14, 147–156.
Bjune, G., Høiby, E. A., Grønnesby, J. K., Arnesen, O., Holst Fredriksen, J., Halstensen, A., et al. (1991) Effect of an outer membrane vesicle vaccine against serogroup B meningococcal disease in Norway. Lancet 338, 1093–1096.
Saunders, N. B., Shoemaker, D. R., Moran, E. E., Larsen, T., and Zollinger, W. D. (1999) Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice. Infect. Immun. 67, 113–119.
Simecka, J. W., Jackson, R. J., Kiyono, H., and McGhee, J. R. (2000) Mucosally induced immunoglobulin E-associated inflammation in the respiratory tract. Infect. Immun. 68, 672–679.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Holst, J., Haneberg, B. (2001). Early Experiences with Nasal Vaccines against Meningococcal Disease. In: Pollard, A.J., Maiden, M.C. (eds) Meningococcal Vaccines. Methods in Molecular Medicine™, vol 66. Humana Press. https://doi.org/10.1385/1-59259-148-5:223
Download citation
DOI: https://doi.org/10.1385/1-59259-148-5:223
Publisher Name: Humana Press
Print ISBN: 978-0-89603-801-1
Online ISBN: 978-1-59259-148-0
eBook Packages: Springer Protocols